
Collaboration to support biotech company’s clinical and commercial production efforts.

Plant is expected to offer packaging, serialization, and third-party contract manufacturing services.

Global air freight market data suggests only a 1.6% demand drop off compared to 2019.

Saint-Beauzire complex dedicated to sterile liquid drug production.

The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

CDMO is commissioning third GMP biologics facility in Fremont.

CDMO will be providing high-quality lentiviral vectors for CAR-T therapies.

Location serves as the US flagship for company’s global pharma development network.

In effort to preserve medication, contribution will provide 150 refrigeration units across 17 countries.

The latest people news happenings over the past month.

Project—which is expected to double plant’s distribution capacity—will be completed by end of Q3.

Citing FDA’s slow guidance, the American Pharmacists Association is requesting delay in November 2023 DSCSA enforcement.

Complex to develop cGMP-compliant, commercial-scale plasmid DNA.

Companies to release variety of options for this sector.

Platform expected to allow customers to meet various logistics requirements, company says.

Expansion expected to help tackle health issues at a faster rate, company says

Annual report finds continuing impact of COVID-19 on global markets

Transaction expected to close early this year

Reflects company’s identity and pharma supply chain impact

Creates Cellular Origins in order to simplify the late-stage development process

North Carolina facility to manufacture Pfizer’s pipeline products

Cold chain company’s supply chain services experience to help facilitate therapy transport

Nottingham location expected to be fully operational by the end of 2023

Platform is expected to streamline batch turnaround times

Acquisition of Texas facility to add 60,000 square feet of manufacturing space to company’s footprint

Provider will be CDMO’s primary material supplier in the lab, clinical, and production settings

Agreement focused on streamlining and automating manufacturing of cell and gene therapies

Partnership aims to lower prescription drug costs and increase price transparency

Global demand for advanced storage devices likely to fuel growth opportunities

Award given in recognition of CDMO’s commitment to promoting sustainable future